Melphalan

tumor protein p53 ; Homo sapiens







22 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34530900 Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma. 2021 Sep 16 1
2 34832966 In Vitro Assessment of the Role of p53 on Chemotherapy Treatments in Neuroblastoma Cell Lines. 2021 Nov 19 1
3 33153480 Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells. 2020 Nov 5 1
4 29295500 Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells. 2017 Dec 23 1
5 26414189 Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support. 2016 1
6 27693638 DNA-PKcs, a novel functional target of acriflavine, mediates acriflavine's p53-dependent synergistic anti-tumor efficiency with melphalan. 2016 Dec 1 1
7 24089038 Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis. 2014 May 1
8 24308434 Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. 2014 Sep 2
9 24913980 Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1. 2014 Jul 15 1
10 25051404 Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma. 2014 Sep 23 1
11 22653969 The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. 2012 Aug 1
12 19417135 Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts. 2009 May 15 1
13 18095870 Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells. 2008 Jan 1
14 18024399 Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. 2007 Nov 2
15 15883412 Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. 2005 Jul 1 2
16 15308759 p53 elevation in relation to levels and cytotoxicity of mono- and bifunctional melphalan-DNA adducts. 2004 Nov 2
17 14555520 Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. 2003 Oct 1 3
18 11507071 Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. 2001 Aug 15 5
19 11050000 Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. 2000 Nov 1 2
20 11096420 Abrogation of G(2)/M-phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells. 2000 Dec 2
21 11107118 p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. 2000 Dec 2
22 8706243 Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein. 1996 Jul 1